Behaviour of plasma citrulline after bariatric surgery in the BARIASPERM cohort.


Journal

Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603

Informations de publication

Date de publication:
02 2021
Historique:
received: 21 12 2019
revised: 28 05 2020
accepted: 30 05 2020
pubmed: 7 9 2020
medline: 24 8 2021
entrez: 6 9 2020
Statut: ppublish

Résumé

Plasma citrulline is currently used in clinical practice as a marker of small bowel functional mass. Behaviour of plasma citrulline after bariatric surgery and its link with post-operative outcome are still poorly understood. Primary objective was to compare plasma citrulline 12 months after two types of bariatric surgery with pre-operative concentrations. Secondary objectives were to search for correlation between plasma citrulline variation and body weight and fat mass loss. This is an ancillary study of the BARIASPERM study. Forty-six adult men (mean age 38.9 ± 7.9 years) who underwent gastric bypass (GB, n = 20) or sleeve gastrectomy (SG, n = 26) were included in this prospective study. Plasma citrulline was measured at baseline, 6 months and 12 months after surgery, as well as total body weight and fat mass measured by dual x-ray absorptiometry (DEXA). Plasma citrulline increased significantly 12 months after surgery, both after gastric bypass and sleeve gastrectomy (respectively 30.2% [18.3-42.2] and 17.8% [5.8-29.7]). The increase was significantly higher after GB than after SG (p = 0.02) while total body weight and fat mass loss were not significantly different between GB and SG. The increase in plasma citrulline levels tended to be positively correlated with both weight and fat mass loss however the association did not reach statistical significance (p = 0.07 and p = 0.06 respectively). These results confirm the increase in plasma citrulline after GB published in two previous small studies. Citrulline also significantly increased after SG, and in spite of similar weight loss obtained with both surgery types, citrulline increase was higher after GB than SG. This suggests different modifications of intestinal functional mass after these two different techniques.

Sections du résumé

BACKGROUND
Plasma citrulline is currently used in clinical practice as a marker of small bowel functional mass. Behaviour of plasma citrulline after bariatric surgery and its link with post-operative outcome are still poorly understood.
OBJECTIVE
Primary objective was to compare plasma citrulline 12 months after two types of bariatric surgery with pre-operative concentrations. Secondary objectives were to search for correlation between plasma citrulline variation and body weight and fat mass loss.
DESIGN
This is an ancillary study of the BARIASPERM study. Forty-six adult men (mean age 38.9 ± 7.9 years) who underwent gastric bypass (GB, n = 20) or sleeve gastrectomy (SG, n = 26) were included in this prospective study. Plasma citrulline was measured at baseline, 6 months and 12 months after surgery, as well as total body weight and fat mass measured by dual x-ray absorptiometry (DEXA).
RESULTS
Plasma citrulline increased significantly 12 months after surgery, both after gastric bypass and sleeve gastrectomy (respectively 30.2% [18.3-42.2] and 17.8% [5.8-29.7]). The increase was significantly higher after GB than after SG (p = 0.02) while total body weight and fat mass loss were not significantly different between GB and SG. The increase in plasma citrulline levels tended to be positively correlated with both weight and fat mass loss however the association did not reach statistical significance (p = 0.07 and p = 0.06 respectively).
CONCLUSION
These results confirm the increase in plasma citrulline after GB published in two previous small studies. Citrulline also significantly increased after SG, and in spite of similar weight loss obtained with both surgery types, citrulline increase was higher after GB than SG. This suggests different modifications of intestinal functional mass after these two different techniques.

Identifiants

pubmed: 32891457
pii: S0261-5614(20)30282-X
doi: 10.1016/j.clnu.2020.05.045
pii:
doi:

Substances chimiques

Citrulline 29VT07BGDA

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

505-510

Investigateurs

F Eustache (F)
M Coupaye (M)
S Msika (S)
R Cohen (R)
J M Catheline (JM)
F Brugnon (F)
K Slim (K)
C Barsamian (C)
J M Chevallier (JM)
M Bretault (M)
J L Bouillot (JL)

Informations de copyright

Copyright © 2020 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of Interest The authors declare no relevant conflict of interest.

Auteurs

François Mifsud (F)

Hôpital Européen Georges Pompidou, Service de Nutrition, Centre Spécialisé Obésité (CSO) Ile-de-France-Sud, APHP-centre, Université de Paris, France.

Sébastien Czernichow (S)

Hôpital Européen Georges Pompidou, Service de Nutrition, Centre Spécialisé Obésité (CSO) Ile-de-France-Sud, APHP-centre, Université de Paris, France; Centre d'Épidémiologie Clinique, Hôpital Hôtel-Dieu, Team METHODS, Paris Cité-CRESS Inserm UMR1153, Paris, France.

Claire Carette (C)

Hôpital Européen Georges Pompidou, Service de Nutrition, Centre Spécialisé Obésité (CSO) Ile-de-France-Sud, APHP-centre, Université de Paris, France.

Rachel Levy (R)

Sorbonne Université, Saint Antoine Research Center, INSERM équipe Lipodystrophies génétiques et acquises, France; Service de biologie de la reproduction-CECOS, AP-HP, Hôpital Tenon, F-75020 Paris, France.

Philippe Ravaud (P)

Centre d'Épidémiologie Clinique, Hôpital Hôtel-Dieu, Team METHODS, Paris Cité-CRESS Inserm UMR1153, Paris, France.

Luc Cynober (L)

Service de Biochimie, Hôpital Cochin, APHP.5, France; EA 4466 PRETRAM, Faculté de Pharmacie, Université de Paris, France.

Nathalie Neveux (N)

Service de Biochimie, Hôpital Cochin, APHP.5, France; EA 4466 PRETRAM, Faculté de Pharmacie, Université de Paris, France.

Claire Rives-Lange (C)

Hôpital Européen Georges Pompidou, Service de Nutrition, Centre Spécialisé Obésité (CSO) Ile-de-France-Sud, APHP-centre, Université de Paris, France; Centre d'Épidémiologie Clinique, Hôpital Hôtel-Dieu, Team METHODS, Paris Cité-CRESS Inserm UMR1153, Paris, France. Electronic address: claire.rives-lange@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH